跳至主要内容
临床试验/NCT01603706
NCT01603706已完成不适用

Radial Strain Imaging-Guided Lead Placement for Improving Response to Cardiac Resynchronization Therapy in Patients With Ischemic Cardiomyopathy: A Randomized Clinical Trial

Sheba Medical Center10 个研究点 分布在 2 个国家目标入组 172 人开始时间: 2012年5月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
172
试验地点
10
主要终点
Demonstrating Percent reduction in left ventricular end systolic (LVESV) at 6 months compared with baseline values.

研究概览

简要总结

The purpose of this study is to evaluate the use of radial strain imaging using speckle tracking analysis to predict the response to CRT in patients with ischemic cardiomyopathy (ICMP) with NYHA functional class 2-4 heart failure and a standard guideline-based CRT indication. Thus assessing the value of lead localization determined by radial strain imaging in a prospective, randomized manner.

详细描述

In this study we propose to evaluate the utility of radial strain imaging using speckle tracking to predict the response to CRT in patients with ischemic cardiomyopathy (ICMP) with NYHA functional class 2-4 heart failure and a standard guideline-based CRT indication, and to determine the value of lead localization determined by radial strain imaging in a prospective, randomized manner. We will compare two randomized groups of CRT recipients implanted with CRT-D systems. In the control group, implantation will be performed in the usual manner and the lead will be placed at the discretion of the implanting physician, preferably at posterolateral LV sites . In the study group, leads will be placed in areas of latest contraction that lack significant scar, as determined by speckle tracking imaging. The primary outcome measure for comparison between the 2 groups will be echocardiographic response (as assessed by percent reduction in left ventricular end systolic volumes) at 6 months post-implantation. In addition, clinical response parameters will also be measured as secondary end points.

We hypothesize that 1) patients showing greater dyssynchrony and/or discoordination index with speckle tracking will derive a significantly greater response to cardiac resynchronization therapy; and 2) patients allocated to the image-guided LV lead placement group will derive a significantly greater response to CRT than patients in the non- guided implantation (control) group.

If radial strain imaging proves useful for improving the CRT response rate and identification of patients likely to respond, it will have important clinical and economic implications by improving individual outcomes and more effective utilization of constrained health care resources. Furthermore, if echo-guided lead implantation proves to be effective in reducing the relatively large non-response rate to cardiac resynchronization therapy, it will likely result in increased device utilization among eligible heart failure patients.

Specific Aims Aim #1: To show that in patients with ischemic cardiomyopathy, implantation of a CRT LV lead guided by radial strain imaging results in a significantly greater echocardiographic and clinical response to cardiac resynchronization therapy compared with conventional implantation techniques.

Aim #2: To show that speckle tracking strain data can be used to identify the degree of echocardiographic response to CRT, using both dyssynchrony (time to peak strain ) and discoordination indices.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with ischemic CMP based on evidence of prior MI by history, coronary angiography/revascularization or imaging
  • AHA ACC or ESC EHRA Guideline-based indication (Class I or II) for CRT and NYHA class II-IV heart failure
  • ECG wide QRS and :
  • QRS > 120 msec in NYHA III- IV
  • CLBBB or QRS > 150 in NYHA =II
  • Sinus rhythm predominant rhythm (PAF not an exclusion)
  • All must be candidates for De novo CRT-D implantation with LV lead via transvenous approach or patients previously implanted with pacemaker or ICD with <20% pacing over the last three months who are undergoing CRT-D upgrade.
  • Patient provides informed consent, tolerate a pectoral implant, agree to comply with the protocol, and maintain scheduled follow-up visits.

排除标准

  • Permanent or persistent atrial fibrillation
  • Advanced renal disease (Cr >=2.5 mg/dL)
  • Advanced comorbidities with life expectancy of <1 year
  • Patients on waiting list for heart transplantation
  • Requiring intravenous amines (continuous or or intermittent amine drip therapy)
  • Severe chronic pulmonary disease (simulating heart failure)
  • Severe (untreated) organic mitral valve disease
  • Poorly treated hypertension
  • History of myocardial infarction < 3 months; unstable angina < 1m, CABG <3 months; PCI <3 months
  • Mechanical TC valve
  • Previously implanted CRT system
  • Poorly visualized cardiac chamber dimensions in an echocardiogram performed prior to enrollment - please help us define
  • Pregnancy or child-bearing potential in the absence of accepted forms of birth control
  • Concurrent enrollment in other study

研究组 & 干预措施

Echo guided implantation group

Active Comparator

Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.

干预措施: Echo guided implantation group (Procedure)

Conventional implantation group

No Intervention

Patients undergoing conventional LV lead implantation

结局指标

主要结局

Demonstrating Percent reduction in left ventricular end systolic (LVESV) at 6 months compared with baseline values.

时间窗: within 12 month from enrollment.

To show that in patients with ischemic cardiomyopathy, implantation of a CRT LV lead guided by radial strain imaging results in a significantly greater echocardiographic and clinical response to cardiac resynchronization therapy compared with conventional implantation techniques.

次要结局

  • Clinical Improvement(Within 12 month from enrollment)
  • Echocardiographic improvement(Within 12 month from enrollment)
  • Improvement in wellbeing(Within 12 month from enrollment)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Prof. Michael Glikson

Prof. Michael Glikson, MD.

Sheba Medical Center

研究点 (10)

Loading locations...

相似试验